12/2
07:10 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Medium
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
11/25
08:00 am
nams
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
Medium
Report
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
11/16
10:33 am
nams
NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating [Seeking Alpha]
Low
Report
NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating [Seeking Alpha]
11/7
04:01 pm
nams
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/6
11:43 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Royal Bank Of Canada from $39.00 to $44.00. They now have an "outperform" rating on the stock.
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Royal Bank Of Canada from $39.00 to $44.00. They now have an "outperform" rating on the stock.
11/5
01:31 pm
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Needham & Company LLC from $40.00 to $46.00. They now have a "buy" rating on the stock.
Medium
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its price target raised by analysts at Needham & Company LLC from $40.00 to $46.00. They now have a "buy" rating on the stock.
11/5
08:00 am
nams
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
Medium
Report
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
10/30
08:00 am
nams
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
Medium
Report
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
10/21
07:28 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Medium
Report
NewAmsterdam Pharma (NASDAQ:NAMS) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
10/20
07:01 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) was given a new $52.00 price target on by analysts at HC Wainwright.
Medium
Report
NewAmsterdam Pharma (NASDAQ:NAMS) was given a new $52.00 price target on by analysts at HC Wainwright.
10/17
07:03 am
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
10/14
07:51 am
nams
Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation [Yahoo! Finance]
Low
Report
Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation [Yahoo! Finance]
10/14
07:07 am
nams
Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation [Yahoo! Finance]
Low
Report
Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation [Yahoo! Finance]
10/14
07:00 am
nams
Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation
Low
Report
Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation
10/14
07:00 am
nams
Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation
Low
Report
Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation
10/8
12:31 pm
nams
NewAmsterdam Pharma (NASDAQ:NAMS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
NewAmsterdam Pharma (NASDAQ:NAMS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/24
08:56 am
nams
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum [Yahoo! Finance]
Low
Report
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum [Yahoo! Finance]
9/24
08:00 am
nams
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
Low
Report
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum